Atezolizumab

High baseline BMI appeared to be independently associated with improved survival among patients with non-small cell lung cancer who received atezolizumab, according to results of a retrospective study published in JAMA Oncology.

SAN ANTONIO — The addition of atezolizumab to neoadjuvant chemotherapy failed to improve pathologic complete response rate for patients with triple-negative breast cancer, according to preliminary results from the randomized NeoTRIPaPDL1 Michelangelo study presented at San Antonio Breast Cancer Symposium.

The FDA approved atezolizumab plus nab-paclitaxel and carboplatin for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer, according to a manufacturer-issued press release.

A combination of atezolizumab and bevacizumab conferred statistically significant and clinically meaningful improvements in PFS and OS compared with sorafenib among patients with unresectable hepatocellular carcinoma, according to results of the randomized phase 3 IMbrave150 study presented at European Society for Medical Oncology Asia Congress.

NATIONAL HARBOR, Md. — Patients who received atezolizumab as first-line monotherapy for metastatic non-small-cell lung cancer showed significant improvement in overall survival, according to phase 3 interim overall survival analysis data of the IMpower 110 trial presented at Society for Immunotherapy of Cancer Annual Meeting.

Lung Cancer Awareness Month — observed every November — is intended to educate the public about the potential causes and risk factors of the disease.

The combination of atezolizumab and bevacizumab prolonged survival compared with standard-of-care sorafenib for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy, according to topline data from the phase 3 IMbrave150 study.

BARCELONA, Spain — The addition of atezolizumab to chemotherapy prolonged PFS for patients with metastatic urothelial cancer, according to results of a randomized phase 3 study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — Atezolizumab significantly prolonged OS compared with platinum-based chemotherapy for patients with newly diagnosed non-small cell lung cancer whose tumors expressed high levels of PD-L1, according to an interim survival analysis from the phase 3 IMpower110 study presented at European Society for Medical Oncology Congress.

Atezolizumab as first-line monotherapy prolonged OS compared with chemotherapy alone for certain patients with non-small cell lung cancer, according to the agent’s manufacturer.